Polyploidization of megakaryocytes was studied in bone marrow aspirates from 3 patients with May-Hegglin anomaly by combined application of cytophotometric determination of the DNA content and autoradiography with 3H-TdR labeling in vitro. A marked elevation of the influx of progenitor cells into the megakaryocytic cell system as well as a decreased maturation capacity from type II to type III megakaryocytes was observed possibly contributing to the pathological platelet sequestration. The polyploidization activity as assessed by 3H-TdR labeling and nuclear DNA content was normal.
14:195-198, 1988.The efficacy and tolerance of denbufylline (25 and 50 mg tid for three months) were investigated in 20 inpatients with cerebrovascular disease in a placebo-controlled, doubleblind parallel study. Denbufylline at 50 mg tid significantly improved the mental, emotional, and social capabilities of the patients; tolerance was acceptable.
The aim of this study was to develop a Croatian Delphi-based expert consensus for screening interstitial lung disease (ILD) associated with connective tissue disease (CTD). A systematic literature review was conducted on risk factors for the development of ILD, prevalence and incidence of ILD, diagnostic and screening methods for ILD, and prognosis of ILD in idiopathic inflammatory myopathy (IIM), mixed connective tissue disease (MCTD), primary Sjögren’s syndrome (pSS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc) were performed. Based on the evidence found, experts developed questionnaires for screening and monitoring ILD in each CTD, which were provided via an online survey. Following the electronic survey, two screening algorithms were developed based on the consensus opinions. The detection strategy for ILD included high-resolution computed tomography (HRCT) in addition to pulmonary function testing for IIM, MCTD, and SSc. and pulmonary function testing for newly diagnosed pSS, RA and SLE. However, in patients with identified risk factors for ILD HRCT, these tests should also be performed. A screening strategy for early identification of patients with various CTD-ILD was first developed by a multidisciplinary team of rheumatologists, pulmonologists, and radiologists to identify early CTD patients at risk of ILD, a severe extra-articular manifestation of CTD.
BackgroundThe International Consensus on Antinuclear Antibody (ANA) Patterns (ICAP) has recently proposed nomenclature in order to harmonize ANA indirect immunofluorescence (IIF) pattern reporting. ICAP distinguishes competent-levelfrom expert-level patterns. A survey was organized to evaluate reporting, familiarity, and considered clinical value of ANA IIF patterns. MethodsTwo surveys were distributed by European Autoimmunity Standardization Initiative (EASI) working groups, the International Consensus on ANA Patterns (ICAP) and UKNEQASto laboratory specialists and clinicians. Results438 laboratory specialists and 248 clinicians from 67 countries responded. Except for dense fine speckled (DFS), the nuclear competent patterns were reported by >85% of the laboratories. Except for rods and rings, the cytoplasmic competent patterns were reported by >72% of laboratories. Cytoplasmic IIF staining was considered ANA positive by 55% of clinicians and 62% of laboratory specialists, with geographical and expertise-related differences. Quantification of fluorescence intensity was considered clinically relevant for nuclear patterns, but less so for cytoplasmic and mitotic patterns.Combining IIF with specific extractable nuclear antigens (ENA)/dsDNA antibody testing was considered most informative. Of the nuclear competent patterns, the centromere and homogeneous pattern obtained the highest scores for clinical relevance and the DFS pattern the lowest. Of the cytoplasmic patterns, the reticular/mitochondria-like pattern obtained the highest scores for clinical relevance and the polar/Golgi-like and rods and rings patterns the lowest. ConclusionThis survey confirms that the major nuclear and cytoplasmic ANA IIF patterns are considered clinically important. There is no unanimity on classifying DFS, rods and rings and polar/Golgi-like as a competent pattern and on reporting cytoplasmic patterns as ANA IIF positive.
croatia / zavod za kliničku imunologiju i reumatologiju, klinika za unutarnje bolesti medicinskog fakulteta sveučilišta u zagrebu, klinički bolnički centar zagreb 2 department of physical medicine, rehabilitation, and rheumatology, national memorial Hospital vukovar, vukovar, croatia / odsjek za fizikalnu medicinu, rehabilitaciju i reumatologiju, nacionalna memorijalna bolnica vukovar, vukovar, Hrvatska corresponding author / Adresa autora za dopisivanje: Darija Čubelić, MD division of clinical immunology and rheumatology / zavod za kliničku imunologiju i reumatologiju department of internal medicine / klinika za unutarnje bolesti University of zagreb, school of medicine / medicinski fakultet sveučilišta u zagrebu University Hospital center zagreb / klinički bolnički centar zagreb kišpatićeva 12 10000 zagreb croatia / Hrvatska tel.
BackgroundSystemic lupus erythematosus (SLE) is frequently not reported in death certificates of lupus patients, despite its known role as an underlying and/or immediate cause of death. Possible reasons may be insufficient access to patients' medical records at time of death (including details on their medical history) and/or physicians' unawareness of the contribution of SLE to death.ObjectivesWe aimed to analyze the extent and predictors of non-reporting of SLE in death certificates of 90 deceased SLE patients regularly followed-up in a routine academic setting at our Department.MethodsWe retrospectively observed 90 SLE patients (68 females) deceased within the 2002–2011 period. All patients were ≥18 years of age and Croatian residents at the time of death, fulfilling ≥4 classification criteria of the American College of Rheumatology (ACR). We identified patients with SLE listed as a cause of death in the death certificate. An extensive set of variables was compared between patients with and without SLE reported in the certificate: demographics, ACR criteria at time of death and damage according to the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC)/ACR index and its components at the time of death. We also compared the proportion of in-hospital deaths and autopsies performed. Frequencies were compared using the χ2 and Fisher's exact test, and continuous variables using the t-test and Mann-Whitney U test. Variables associated with reporting of SLE in the death certificate in the univariate analysis were included in a multivariate logistic regression model.ResultsSLE was reported in death certificates of 41/90 (46%) patients. Patients with SLE not reported in their death certificates were older at death (62±14 vs. 53±15 years) and diagnosis (53±14 vs 42±18 years) and had a longer time from their last visit at our Department to death (0.80±1.00 vs. 0.34±0.66 years), compared to patients with SLE listed in the death certificate (p<0.05). They also had a lower proportion of renal disorder (20/49 vs. 29/41), cardiovascular and pulmonary damage (18/49 vs. 28/41 and 7/49 vs. 13/41, respectively), and died less frequently in hospital (28/49 vs. 35/41) and due to infections (4/49 vs. 26/41) (p<0.05). Conversely, these patients had a higher frequency of malignancy as a feature of damage (17/49 vs. 6/41) and a cause of death (14/49 vs. 1/41) (p<0.05). Only patients without SLE listed in their death certificate accrued gastrointestinal damage (7/49 vs. 0/41, p=0.015), hence this type of damage could not be included in the multivariate logistic model. In the multivariate model, the presence of infection as a cause of death was the single variable related to (non-)reporting of SLE (OR 0.053; 95% CI 0.012–0.237) (Table 1).Table 1.Predictors of non-reporting of SLE in death certificates (OR: odds ratio; CI: confidence interval)ConclusionsNon-reporting of SLE in death certificates of lupus patients may be an obstacle towards assessing the true extent of SLE-related mortality, calling into question the re...
BackgroundThe International Consensus on Antinuclear Antibody (ANA) Patterns (ICAP) has recently proposed nomenclature in order to harmonize ANA indirect immunofluorescence (IIF) pattern reporting. ICAP distinguishes competent-level from expert-level patterns. A survey was organized to evaluate reporting, familiarity, and considered clinical value of ANA IIF patterns. MethodsTwo surveys were distributed by European Autoimmunity Standardization Initiative (EASI) working groups, the International Consensus on ANA Patterns (ICAP) and UK NEQAS to laboratory professionals and clinicians. Results438 laboratory professionals and 248 clinicians from 67 countries responded. Except for dense fine speckled (DFS), the nuclear competent patterns were reported by >85% of the laboratories. Except for rods and rings, the cytoplasmic competent patterns were reported by >72% of laboratories. Cytoplasmic IIF staining was considered ANA positive by 55% of clinicians and 62% of laboratory professionals, with geographical and expertise-related differences. Quantification of fluorescence intensity was considered clinically relevant for nuclear patterns, but less so for cytoplasmic and mitotic patterns. Combining IIF with specific extractable nuclear antigens (ENA)/dsDNA antibody testing was considered most informative. Of the nuclear competent patterns, the centromere and homogeneous pattern obtained the highest scores for clinical relevance and the DFS pattern the lowest. Of the cytoplasmic patterns, the reticular/mitochondria-like pattern obtained the highest scores for clinical relevance and the polar/Golgi-like and rods and rings patterns the lowest. ConclusionThis survey confirms that the major nuclear and cytoplasmic ANA IIF patterns are considered clinically important. There is no unanimity on classifying DFS, rods and rings and polar/Golgi-like as a competent pattern and on reporting cytoplasmic patterns as ANA IIF positive.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.